Fairvalue-Calculator Fairvalue-Calculator
EN DE

Helix BioMedix, Inc (HXBM) Fair Value & Analysis

Healthcare · US · Market cap $402K

Price$1.79
Fair Value$6.84
Upside+282.1%
Quality95/100
Evidence: Low Range $4.51 – $8.54

Fair value as of: Jun 25, 2026

Analysis

Helix BioMedix, Inc (HXBM) currently trades at $1.79, while our model-based Fair Value estimate is $6.84 — implying the stock looks roughly 282.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Helix BioMedix, Inc (HXBM) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $6.84 versus a price of $1.79 — about +282% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HXBM?
Our 21-model fair value for Helix BioMedix, Inc is $6.84 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.79.
What is the quality score of HXBM?
Helix BioMedix, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.